Tag: ADVANTAGE AF
Second phase of Boston’s ADVANTAGE AF study meets primary safety and...
Boston Scientific has announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the...
New data presented on Farapulse and Watchman FLX devices at AF...
Boston Scientific announced data supporting the use of the Farapulse pulsed field ablation (PFA) system and the Watchman FLX left atrial appendage closure (LAAC) device,...